Which GLP-1 is better? A March research review comparing tirzepatide and semaglutide lands on a nuanced answer: one tends to win on weight and metabolism, the other has the strongest heart evidence.
A March 2026 narrative review comparing tirzepatide and semaglutide concluded that tirzepatide tends to show superior metabolic and weight-loss efficacy in direct comparisons, while semaglutide currently has the strongest cardiovascular-outcomes evidence. The takeaway is individualization: the better choice depends on a patient priorities and clinical profile, not a single winner.
As GLP-1 use broadens, the practical question many patients ask is simply which one.
A March research review tackled the tirzepatide-versus-semaglutide comparison directly.
The review synthesized clinical-trial evidence comparing tirzepatide (a dual GLP-1 and GIP receptor agonist) with semaglutide (a GLP-1 receptor agonist) across obesity, glycemic control, and cardiovascular outcomes. Its broad conclusion: tirzepatide tends to demonstrate greater metabolic efficacy, including weight loss and blood-sugar control, in head-to-head data, whereas semaglutide currently carries the strongest evidence base for cardiovascular benefit, anchored by dedicated outcomes trials.
Rather than crowning a universal winner, the review emphasized individualized treatment selection based on clinical priorities, for example, maximizing weight or glycemic control versus prioritizing established cardiovascular risk reduction, along with tolerability, access, and cost. This mirrors how clinicians increasingly frame the choice: matching the medicine to the person.
For consumers, the useful message is that better depends on goals. Someone focused on maximal weight or metabolic improvement may weigh the evidence differently than someone with established cardiovascular disease. Comparative reviews summarize averages and trends, not individual guarantees, and they cannot account for personal history, side-effect tolerance, or insurance realities. The choice is a clinical conversation, not a leaderboard.
Watch for more head-to-head trials and longer-term outcomes data, including from newer agents and combinations, which could shift these comparisons. Cardiovascular and other indication expansions may also change how each drug is positioned. For individuals, the practical step is to bring personal priorities, weight, metabolic health, heart risk, tolerability, cost, to a prescriber, who can weigh them against the current evidence rather than defaulting to whichever drug is most discussed.